Is Iboga the New Poster Child for Decriminalizing Psychedelics?
Many of the most widely used recreational drugs have their origins in plants whose psychoactive effects have been known for centuries to people in the plants’ native range. For decades before states began implementing medical cannabis programs, advocates were saying that marijuana comes from a plant and is therefore a healthy way to treat nausea and anxiety, that it has more in common with arugula than with Prozac. Yes, said the “drugs are bad” folks, but cocaine and heroin come from plants, too, and they are plenty dangerous. Now that cannabis is legal in all but name in so many states, public discourse has extended to other recreational drugs that people use to self-medicate. In online discussion forums, it is one person’s word against another’s whether LSD and MDMA are worse for you than the drugs that psychiatrists prescribe to treat depression, anxiety, and post-traumatic stress disorder (PTSD). In these online spaces, you find patients frustrated with taking prescription drugs and experiencing only a limited improvement in symptoms, to say nothing of the havoc it wreaks on their physical and emotional states when they change medications. It is not possible to settle the matter of whether there is value in using psychedelics to treat psychiatric conditions or whether the proponents of psychedelically induced mental health are tripping, pharmacologically or figuratively. To reach any resolution, you need clinical trials, and it is virtually impossible to get legal authorization for clinical trials on Schedule I controlled substances like cannabis, psilocybin, and MDMA. Here, our Miami drug crimes defense lawyer explains the recent executive order that allows clinical trials on iboga and other psychedelics currently classified as Schedule I drugs.
Iboga in Traditional African Medicine
Iboga is the Mwene language name for the tree known in Latin binomial nomenclature as Tabernanthe iboga. The tree grows in Gabon, Democratic Republic of Congo, and Republic of Congo in central Africa. It has probably been part of the region’s traditional medicine for centuries, if not for millennia, but the first written references to it comes from descriptions by French explorers who visited central Africa in the 19th century. They said that people would chew the roots of the plant for its stimulant effects, especially during ceremonies that involved dancing late into the night. The people would also drink a beverage made from iboga roots during an initiation ritual that requires participants to undergo an out-of-body experience, much like the rituals involving entheogen-induced trances in other parts of the world. In other words, iboga is a stimulant at low doses and a hallucinogen at high doses.
Iboga Can Reduce Drug Cravings, but at What Cost?
Iboga is one of the many psychedelic drugs that people have claimed reduces their cravings for addictive drugs such as opioids or alcohol. Therefore, the demand for clinical trials on iboga centers on its potential as a treatment for substance use disorder. The biggest risk of iboga is that it can cause cardiac dysfunction, especially at the doses required to produce hallucinogenic effects. People who have recently taken iboga tend to experience a condition called long QT syndrome (LQTS), where the QT interval, which is the pause between heartbeats, is longer than normal. It is especially dangerous in people who have a history of heart problems.
The New Executive Order on Psychedelic Research
In April 2026, President Trump signed an executive order authorizing clinical trials on several psychedelic drugs, including psilocybin, which is the active ingredient in magic mushrooms, and ibogaine, which is the active ingredient in iboga. Both drugs are currently listed as Schedule I controlled substances, so the clinical trials would not be legal without this executive order. The clinical trials will investigate the potential of these drugs to treat post-traumatic stress disorder (PTSD) and substance use disorder. Veterans’ Affairs hospitals will be the first to conduct the clinical trials, since PTSD is so prevalent among combat veterans. One of the attendees at the ceremony where President Trump signed the executive order was Marcus Luttrell, the author of a memoir about his experiences serving in the war in Afghanistan in the early 2000s and then suffering from PTSD before finding relief from his symptoms through psychedelics.
Contact Our Criminal Defense Attorneys
A South Florida criminal defense lawyer can help you if you are facing criminal charges for illegal possession, sale, or distribution of psychedelic drugs, even if you only use them to treat chronic health conditions. Contact Ratzan & Faccidomo in Miami, Florida for a confidential consultation about your case.
Source:
npr.org/2026/04/18/nx-s1-5789859/psychedelic-treatments-mental-health
